Arcellx, Inc. ACLX 深 沪
已收盘 12-19 16:00:00 美东时间
64.00
-0.130
-0.20%
华盛通- 最 高79.75
- 今 开64.52
- 成交量 61.27万股
- 最 低 63.48
- 昨 收 64.13
- 总市值 22.87亿
- 52周最高 94.07
- 市盈率 静 --
- 换手率 1.71%
- 52周最低 49.00
- 委 比 -77.44%
- 总股本 3573.66万
- 历史最高 107.3699
- 量 比 0.57
- 振 幅 25.37%
- 历史最低 1.10
- 每 手 1
- 风险率 8.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Is Arcellx Stock Surging Today?
Arcellx shares updated ASH data showing strong response and survival results for anito-cel in relapsed multiple myeloma, with analysts highlighting its emerging profile.
12-09 02:23
Reported Saturday, Anito-Cel Demonstrates 96% ORR And 74% CR/sCR In iMMagine-1 Relapsed/Refractory Multiple Myeloma, Supporting Planned 2026 Commercial Launch
Anito-cel demonstrated 96% ORR and 74% CR/sCR at a median follow-up of 15.9 months; responses continue to deepen over time --Overall MRD negativity was 95% and sustained MRD negativity for >6 months was 83%, both at
12-08 16:47
Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
Aclaris Therapeutics starts Phase 2 trial of bosakitug for moderate-to-severe atopic dermatitis. Bosakitug shows strong potency and affinity to TSLP, with top line results expected in H2 2026.
06-02 10:59
Cantor Fitzgerald Reiterates Overweight on Arcellx
Cantor Fitzgerald analyst Josh Schimmer reiterates Arcellx (NASDAQ:ACLX) with a Overweight.
2024-09-10 00:45
Cantor Fitzgerald Initiates Arcellx at Overweight
07:04 AM EDT, 09/03/2024 (MT Newswires) -- Arcellx (ACLX) has average rating of buy and price targets ranging from $70 to $87, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europ...
2024-09-03 19:04
